Q2 EPS Estimate for TuHURA Biosciences Raised by Analyst

TuHURA Biosciences (NASDAQ:HURA) – Research analysts at HC Wainwright boosted their Q2 2026 earnings per share estimates for TuHURA Biosciences in a research note issued to investors on Thursday, April 3rd. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.10) for the quarter, up from their previous estimate of ($0.11). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock.

A number of other research analysts have also issued reports on the stock. Rodman & Renshaw began coverage on shares of TuHURA Biosciences in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price on the stock. RODMAN&RENSHAW raised shares of TuHURA Biosciences to a “strong-buy” rating in a research note on Thursday, December 19th.

TuHURA Biosciences Trading Down 0.6 %

Shares of NASDAQ:HURA opened at $3.38 on Monday. The firm has a fifty day moving average of $3.42. TuHURA Biosciences has a 52-week low of $1.80 and a 52-week high of $7.93.

Hedge Funds Weigh In On TuHURA Biosciences

Several institutional investors have recently added to or reduced their stakes in HURA. Accent Capital Management LLC purchased a new stake in TuHURA Biosciences in the 4th quarter valued at about $29,000. TT Capital Management LLC acquired a new stake in shares of TuHURA Biosciences in the fourth quarter worth approximately $41,000. Jefferies Financial Group Inc. purchased a new stake in TuHURA Biosciences in the fourth quarter valued at approximately $54,000. Bank of America Corp DE acquired a new position in TuHURA Biosciences during the fourth quarter worth approximately $59,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in TuHURA Biosciences during the fourth quarter worth approximately $61,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.